Q-omics provides the consensus-scored TRAV1-2 profile across patient tissues and cancer cell-line models. TRAV1-2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRAV1-2 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, TRAV1-2 RNA expression shows 12,361 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, KIRC, and THYM as cancer lineages where TRAV1-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAV1-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAV1-2 survival associations across molecular data types. TRAV1-2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAV1-2 RNA expression–survival associations across cancer types. High TRAV1-2 expression shows unfavorable associations in LGG, but favorable associations in SKCM, HNSC, UCEC, BRCA and OV. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TRAV1-2 RNA expression.
This table summarizes TRAV1-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAV1-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAV1-2 shows lower tumor expression in LUSC, COAD and THCA and higher tumor expression in KIRC, KIRP and BRCA. The KIRC box plot shows higher TRAV1-2 RNA expression in tumor versus normal tissue (log2 FC = +1.176, t-test p < 0.001).
This table shows molecular features associated with TRAV1-2 in patient tissues and cancer cell lines. In patient samples, TRAV1-2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
